Protagonist Therapeutics (PTGX) Stock Price & Analysis

PTGX$130.95-3.43 -2.55%
BiotechnologyGrowth StockHigh Quality
Compare
Market cap$8.55BEnterprise value$8.28BRevenue (TTM)$551.69MMarket position—

Score

68
Bullish
Value
34
Quality
77
Growth
93

AI Analysis

Snapshot

Protagonist Therapeutics doesn’t screen as a clean setup today — Stocklytics 68/100 leaves more to prove. Under the hood: P/E 26.1, plus revenue compounding ~220% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

34
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

93
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

77
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Protagonist Therapeutics, Inc. (PTGX) last printed $130.95. Equity value is $8.55B. Trailing earnings multiple 24.97. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$20.06M$30.93M$231,000.00$28.63M$27.36M$26.58M$60M$434.43M$46.02M

About

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Protagonist Therapeutics (PTGX) Stock Price & Analysis

PTGX price $130.95 -3.43 -2.55%

Ticker
PTGX
Price
$130.95
Change
-3.43 -2.55%
Market cap
$8.55B
P/E
24.97
Forward P/E
144.00
Dividend yield
0.00%
Beta
1.79
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
68
Value
34
Quality
77
Growth
93

Stocklytics score rationale: value 34, quality 77, growth 93.

AI Score 65. Protagonist Therapeutics, Inc. has a market cap of $9.28 billion and is engaged in promising Phase II clinical trials for its therapies, indicating potential growth

Insights · Forecast · Financials · Learn

Stocklytics home · Screener